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Background: The aim of the present randomised controlled non-inferiority trial is to test whether in women with
compromised ovarian reserve requiring in vitro fertilisation, a protocol of ovarian stimulation using exclusively
clomiphene citrate performs similarly to a regimen with high doses of gonadotropins.
Methods: Women with day 3 serum FSH > 12 IU/ml on at least two occasions or previous poor response to
hyper-stimulation were recruited at four Italian infertility units. Selected women were allocated to clomiphene
citrate 150 mg/day from day 3 to day 7 of the cycle (n=145) or to a short protocol with GnRH agonist 0.1 mg and
recombinant FSH 450 IU daily (n=146). They were randomised by means of a computer-generated list into two
groups. The study was not blinded. The main outcome of the study was the delivery rate per started cycle.
Results: The study was interrupted after the scheduled two years of recruitment before reaching the sample size.
148 women were allocated to clomiphene citrate and 156 to the short protocol with high doses of gonadotropins;
124 and 125 participants were analysed in the groups, respectively. Women allocated to high doses of
gonadotropins retrieved more oocytes and had a higher probability to perform embryo-transfer. However, the
chances of success were similar. The delivery rate per started cycle in women receiving clomiphene citrate and
high-dose gonadotropins was 3% (n=5) and 5% (n=7), respectively (p=0.77). The mean estimated cost per delivery
in the two groups was 81,294 and 113,107 Euros, respectively. No side-effects or adverse events were observed.
Conclusions: In women with compromised ovarian reserve selected for in vitro fertilisation, ovarian stimulation
with clomiphene citrate or high-dose gonadotropins led to similar chances of pregnancy but the former is less
expensive.
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Management of women with compromised ovarian re-
serve selected for in vitro fertilisation (IVF) is challen-
ging. Affected women retrieve less oocytes, have less
embryos for transfer and their chances of success are
generally markedly lower. Not infrequently, their cycles
have to be cancelled due to the absence of follicular
growth, the lack of oocytes retrieved or because of fail-
ure to develop embryos [1-4]. Several strategies have
been proposed to overcome this frustrating situation.
They include an increase in the starting doses of gona-
dotropins, the use of regimens that are alternative to
the long protocol such as the short protocol or the
GnRH antagonist protocol or the natural cycle and the
addition of LHorHCG,GrowthHormone (GH) orGrowth
Hormone Releasing Factor (GHRF), pyridostigmine, L-
arginine, androgens, clomiphene citrate or letrozole [1-5].
Evidence for these approaches is however scarce and
results have been disappointing. In light of this uncer-
tainty, most physicians simply adopt a traditional and in-
tuitive attitude consisting of increasing the starting dose
of gonadotropins (typically 300–450 IU per day) [1]. How-
ever, this choice contrasts with the currently growing
importance given to the idea of friendly IVF. There is
increased attention in securing IVF with a low interven-
tion level, low risks and few side effects [6]. Moreover,
women with compromised ovarian reserve selected for
IVF should not be exclusively viewed as a therapeutic chal-
lenge. The low rate of success and the increased costs of
alternative protocols (in particular those entailing the use
of high doses of gonadotropins) also pose an economical
dilemma. One has to wonder about the rationale of
employing expensive regimens that are not supported by
scientific evidence.
On these bases, we designed a prospective multicentre
non-inferiority Randomised Controlled Trial (RCT)
comparing clomiphene citrate and a short protocol with
high doses of gonadotropins in women with compro-
mised ovarian reserve requiring IVF. The main aim was
to test the hypothesis that a low-cost regimen of exclu-
sively clomiphene citrate is similarly effective or only
slightly worse than a regimen with high doses of
gonadotropins.
Methods
Four Italian centres participated in this study. They were
the infertility units of the following institutions: 1) Fon-
dazione Cà Granda, Ospedale Maggiore Policlinico,
Milan; 2) Istituto Clinico Humanitas, Rozzano; 3) Istituti
Clinici Zucchi, Monza; 4) Università Vita-Salute, Fonda-
zione Ospedale San Raffaele, Milan. Patients referring to
these units between September 2008 and August 2010
and selected for IVF were evaluated for study entry. In-
clusion criteria were similar to those used in previoustrials that established efficacy of the standard high dose
treatment [1] and were as follows: 1) indication to IVF-
ICSI; 2) age 18–42 years; 3) day 3 serum FSH > 12 IU/
ml on at least two occasions or previous poor response
(≤ 3 oocytes with a conventional stimulation protocol)
in a previous IVF cycle. Exclusion criteria were as fol-
lows: 1) number of previous IVF cycles ≥ 3; and 2) cycles
requiring the use of spermatozoa from MESA-TESE pro-
cedures. Before entering the study, the protocol was
explained to patients and a written consent was obtained
from patients agreeing to participate. Consent forms and
the protocol were approved by the local ethical commit-
tees. The study was registered on www.clinicaltrials.gov
with ref. NCT01389713.
Women were evaluated for study entry the month be-
fore the IVF cycle. If eligible and consenting to participate,
they were randomised by means of a computer-generated
list into two groups. An independent list was established
for each study centre. Sealed opaque envelopes containing
treatment allocation were opened after inclusion. Patients
and physicians were not blinded to the treatment alloca-
tion. The two arms of the study were as follows: 1)clomi-
phene citrate oral tablets (ClomidW; Bruno Farmaceutici,
Rome, Italy)at the dose of 150 mg/day from day 3 to day 7
of the cycle; or 2) daily s.c. injections of triptoreline (Deca-
peptylW; 0.1 mg, Ipsen, Milan, Italy) started on day one or
two of the menstrual cycle and 450 IU of s.c. recombinant
FSH (Gonal FW; 450–900 UI pen; Merck Serono, Bari,
Italy) from day 3 of the cycle. The standard treatment was
administered according to that established in previous
trials [1,3]. Subjects of both groups were monitored simi-
larly. Transvaginal US scans were performed on days 3
and 7 of the cycle in all women. Subsequent scans were
individualized based on ovarian response. Serum levels of
peripheral oestrogens and progesterone were done if
deemed necessary. The hCG triggering of ovulation (Ovi-
trelleW; 250 μg, sc; Merck Serono, Bari, Italy) was per-
formed when ultrasound revealed at least one follicle with
a mean diameter ≥ 18 mm. Subjects underwent ovum
pick-up 36 hours later. The dose of recombinant FSH
could not be increased but could be reduced in cases of
hyper-response. Cycles were cancelled due to hyper-
response (>20 follicles with a mean diameter >10 mm at
the time of hCG) or low response (absence of follicular
growth) or inadequate follicular development (arrest of
follicular growth or premature luteinisation). Standard
IVF or Intracytoplasmic Sperm Injection (ICSI) proce-
dures were performed according to standardised criteria
[7] and embryo transfer was executed on day 2 or 3. Luteal
phase supplementation consisted of vaginal micronised
progesterone tablets (ProgeffikW 200 mg, Effikitalia,
Milan, Italy) 200 mg twice a day for 12 days starting the
day of oocytes retrieval. Medications were free of charges
for the patients of both groups since they are routinely
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Women were enrolled for one treatment cycle. Clinical
pregnancy was defined as the ultrasound visualisation of
at least one intrauterine gestational sac. Delivery refers to
viable infants born after 24-weeks gestation. First preg-
nancy ultrasound was performed in the participating in-
fertility units whereas the course of pregnancy was
assessed through telephone contact and by consulting
charts of the obstetrical departments of the participating
institutes.
The main outcome of the study was the delivery rate
per started cycle. The sample size was calculated based
on the following assumptions: 1) study design was a
non-inferiority trial; 2) type I error: one-sided 95% confi-
dence interval (CI); 3) study power = 80%; and 4)
expected delivery rate in the standard treatment group
(high doses of gonadotropins) = 5%. This information
was based on a previous study of our group in this spe-
cific population [5]; 5) largest difference to be regarded
as negligible in favour of the standard treatment = 5%.
On this basis, we calculated a sample size of 472 sub-
jects (236 per arm). Based on an estimate made before
initiating the study on the frequency of the studied con-
dition in the participating centres, a recruitment period
of two years was deemed sufficient to complete the
scheduled sample size. The maximal duration for enrol-
ment was thus set a priori at two years to prevent biases
due to an exceedingly long recruitment period. Data was
compared using the chi-square test, Fisher exact test,
Student’s t-test and non-parametric Wilcox on test as
appropriate (SPSS 18.0 for Windows, Chicago, IL, USA).
A logistic regression model was used to adjust for age
and baseline variables found to differ between the study
groups. A binomial distribution model was used to cal-
culate the 95%CI of proportions.
The perspective of the cost analysis was the one of the
health provider, i.e. costs supported by the public health
system. Costs supported by the individuals (transports,
absences from work, etc.) were excluded. All considered
costs were estimations. We included those for pharma-
cological compounds and those for the IVF procedure.
The former were obtained through the consultancy of
the website of the official Italian Institute for drugs AIFA
(Agenzia Italiana del Farmaco) [8]. They relate to the
price of the entire boxes (the costs of the non-used
ampoules or tablets were not subtracted). Costs for the
IVF cycles were derived from the regional Drugs Related
Groups (DRG) costs [9]. They were as follows: 225
Euros for cycle preparation and monitoring; 2,232 Euros
for oocytes collection; and 2,194 Euros for embryo-
transfer. Only drugs administered domiciliary were
included in the costs (ClomidW, Gonal-FW, DecapeptylW,
OvitrelleW, ProgeffikW). Those administered in the hos-
pital were excluded since already part of the DRG costsof the IVF procedures. Costs of the ultrasound (US)
scans and serum tests were excluded for the same rea-
son. Costs related to pregnancy assistance were excluded
from the model. The direct and indirect costs supported
by the patients and their partners for referrals were also
excluded.
Results
The study was interrupted after the scheduled two years
of recruitment before reaching the sample size of 472
subjects. At this time, 304 women (64% of those sched-
uled) had been enrolled: 148 were allocated to clomi-
phene citrate and the remaining 156 to the short
protocol with high doses of gonadotropins. Thirteen
women (three in the clomiphene citrate group and ten
in the high-dose gonadotropins group) dropped out
prior to initiating the cycle for reasons unrelated to the
prescribed regimen, leaving 291 women for data analysis.
The study power was thus 60% rather than 80% as ini-
tially planned. The precise flow-chart of the study is
shown in Figure 1.
Baseline characteristics of the women in the two study
groups are shown in Table 1. No statistically significant
differences emerged with the exception of the duration
of infertility that was slightly longer in women allocated
to high-dose gonadotropins. Twenty-one cycles per
study group were cancelled during the stimulation
(Table 2). Reasons for cancellation (Figure 1) were iden-
tical: no follicular growth (21 and 21 women), arrested
follicular growth (3 and 3 women) and premature lutei-
nisation (7 and 7 cases). All women in the clomiphene
citrate group assumed the whole prescribed regimen. In
women undergoing the short protocol with high doses
of gonadotropins, the mean total dose of recombinant
FSH given was 4029±1279 IU. Cycle outcome is illu-
strated in Table 2. A significantly higher number of folli-
cles developed with the administration of high-dose
gonadotropins (p<0.001) and a higher number of oocytes
were retrieved during ovum pick-up (p<0.001). A lower
proportion of women in the clomiphene citrate group
performed the embryo transfer (p=0.008). The mean
number of transferred embryos was similar between the
group seven if it tended to be higher in the high-dose
gonadotropins group (p=0.06). The clinical pregnancy
rate per started cycle in the clomiphene citrate and
high-dose gonadotropins groups was 5% (95%CI: 2-10%)
and 6% (95%CI: 3-11%), respectively (p=1.00). The im-
plantation rate was similar. One twin pregnancy was
recorded in the clomiphene citrate group while one
twin and one triplet pregnancy occurred in the high-
dose gonadotropins group: no vanishing twins were
observed and all multiple pregnancies ended in deliv-
ery of viable infants. The delivery rate did not differ. It
was 3% (95%CI: 1-7%) and 5% (95%CI: 2-9%) in the
Assessed for eligibility (n=490) 
Excluded  (n=186) 
♦ Not meeting inclusion criteria (n=50) 
♦ Declined to participate (n=103) 
♦ Other reasons (n=33) 
Analysed  (n=124) 
♦Excluded from analysis (n=0)
Lost to follow-up  (n=0) 
Discontinued intervention (for inappropriate 
response) (n=21)
Allocated to intervention “Clomiphene”  
(n=148) 
♦Received allocated intervention (n=145)
♦Did not receive allocated intervention 
(personal reasons unrelated to the 
treatment) (n=3 )
Lost to follow-up (n=0) 
Discontinued intervention (for inappropriate 
response) (n=21) 
Allocated to intervention “High dose rFSH” 
(n=156) 
♦Received allocated intervention (n=146)
♦Did not receive allocated intervention 
(personal reasons unrelated to the 
treatment) (n=10)
Analysed  (n=125) 
♦Excluded from analysis (n=0)
Randomized (n=304) 
Figure 1 Flow chart of the study.
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groups, respectively (p=0.77). The risk difference of de-
livery was +0.02 (95%CI: -0.03 to +0.07) for the high-
dose gonadotropins group. The Odds Ratio (OR) of
delivery for the clomiphene citrate group compared toTable 1 Baseline characteristics of the study groups
Characteristics Clomiphene
(n=145)
High dose rFSH
(n=146)
p
Age (years) 38.6 ± 2.9 38.5 ± 3.1 0.76
BMI (Kg/m2) 22.0 ± 2.7 22.0 ± 3.0 0.95
Duration of infertility (years) 3.5 ± 2.0 4.1 ± 2.2 0.02
Smoking 29 (20%) 27 (18%) 0.74
Previous pregnancies 42 (29%) 46 (32%) 0.69
Previous ovarian surgery 30 (21%) 27 (18%) 0.64
Cycle length (days) 27.2 ± 3.0 27.4 ± 2.4 0.71
Previous IVF cycles 44 (30%) 37 (25%) 0.34
Day 3 serum FSH (IU/ml) 14.6 ± 8.9 13.6 ± 9.0 0.68
AMH (ng/ml) 0.71 ± 1.0 0.76 ± 1.0 0.67
Total AFC 3.4 ± 2.5 3.9 ± 2.6 0.10
Data are expressed as mean ± SD or number (percentage).high-dose gonadotropins group and adjusted for age
and duration of infertility was 0.80 (95%CI: 0.25-2.63).
All the analyses were repeated considering separ-
ately women whose diagnosis of compromised ovarian
reserve was based on a previous poor response cycle
(≤ 3 oocytes with a conventional stimulation proto-
col) and those whose diagnosis was based exclusively
on persistent elevated day 3 serum FSH. In these two
subgroups, baseline characteristics according to treat-
ment allocation did not differ (data not shown). The
cycle outcome is summarised in Table 3. Overall,
results from this analysis were in line with those
observed for the entire cohort. Finally, we retrospect-
ively evaluated the proportion of the recruited women
who could be classified as poor responders before
study entry according to the new definition proposed
by the Consensus Conference of Bologna [4]. We
found that at least 278 of them (96%) fulfilled these
criteria. All the analyses were repeated focussing ex-
clusively on this subgroup of women and results were
similar (data not shown).
During the study period, the delivery rates in the four
participating units ranged from 16 to 20%, in line with
the data of the national Italian Assisted Reproductive
Table 2 IVF-ICSI cycle outcome in the two study groups
Characteristics Clomiphene (n=145) High dose rFSH (n=146) p
Cancelled cycles 21 (14%) 21 (14%) 1.00
Number of follicles > 15 mm a 1.7 ± 1.1 2.8 ± 1.9 <0.001
Total number of follicles > 10 mm a 2.5 ± 1.4 4.1 ± 2.6 <0.001
Number of oocytes retrieved a 1.1 ± 1.1 2.0 ± 1.8 <0.001
0 52 (42%) 29 (23%)
1-2 58 (47%) 57 (46%) <0.001
≥ 3 14 (11%) 39 (31%)
Fertilisation rate b 75% (93/124) 70% (164/236) 0.33
Women performing Embryo Transfer 56 (39%) 79 (54%) 0.008
Number of embryos transferred c 1.5 ± 0.7 1.7 ± 0.7 0.06
1 33 (59%) 33 (42%)
2 18 (32%) 35 (44%) 0.14
3 5 (9%) 11 (14%)
Number of pregnant women 8 9
PR per started cycle 5% (8/145) 6% (9/146) 1.00
PR per retrieval 6% (8/124) 7% (9/125) 1.00
PR per embryo transfer 14% (8/56) 11% (9/79) 0.81
Embryos implanted (implantation rate) 11% (9/84) 9% (12/136) 0.64
Number of live birth deliveries 5 7
DR per started cycle 3% (5/145) 5% (7/146) 0.77
DR per retrieval 4% (5/124) 6% (7/125) 0.78
DR per embryo transfer 9% (5/56) 9% (7/79) 1.00
Data are expressed as mean ± SD or number (percentage) or median (interquartile range) or percentage (ratio).
a Refers to women who underwent oocyte retrieval.
b Refers to all oocytes used.
c Refers to women performing embryo transfer.
PR: Clinical pregnancy rate. DR: Delivery Rate.
Table 3 IVF-ICSI cycle outcome in the two study groups
Previous Poor response Day 3 serum FSH > 12 UI/ml
Clomiphene
(n=120)
High dose rFSH
(n=118)
p Clomiphene
(n=25)
High dose rFSH
(n=28)
p
Cancelled cycle 16 (3%) 18 (15%) 0.67 5 (20%) 3 (11%) 0.29
Number of oocytes retrieved a 1.4 ± 1.1 2.8 ± 2.4 0.001 2.2 ± 0.8 2.8 ± 1.2 0.23
Fertilisation rate b 88% (83/94) 69% (132/190) 0.001 50% (10/20) 67% (31/46) 0.27
Women performing embryo transfer 50 (42%) 61 (52%) 0.12 6 (24%) 18 (64%) 0.004
Number of embryos transferred c 1.5 ± 0.7 1.8 ± 0.7 0.08 1.3 ± 0.5 1.6 ± 0.6 0.33
PR per started cycle 7% (8/120) 7% (8/118) 0.97 0% (0/25) 4% (1/28) 0.53
PR per embryo transfer 16% (8/50) 13% (8/61) 0.44 0% (0/6) 6% (1/18) 0.75
Embryos implanted (implantation rate) 12% (9/76) 9% (10/107) 0.63 0% (0/8) 7% (2/29) 1.00
DR per started cycle 4% (5/120) 5% (6/118) 0.74 0% (0/25) 4% (1/28) 0.53
DR per embryo transfer 10% (5/50) 10% (6/61) 1.00 0% (0/6) 6% (1/18) 0.75
Data are expressed as mean ± SD or number (percentage) or percentage (ratio).
a Refers to women who underwent oocyte retrieval.
b Refers to all oocytes used.
c Refers to women performing embryo transfer.
PR: Clinical pregnancy rate. DR: Delivery Rate.
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were healthy. In order to identify predictive factors of
delivery in our population, we performed a logistic re-
gression analysis including baseline characteristics of the
patients and study arm as covariates. None of them
showed a significant association with delivery (data not
shown). All the analyses were repeated separately for the
four participating centres and results were similar (data
not shown). No adverse events were observed during the
trial in both groups of intervention.
The different invoice costs for the two therapeutic
regimens are shown in Table 4. The mean costs per
cycle were 2,803 and 5,423 Euros for the clomiphene cit-
rate and high-dose gonadotropins groups, respectively.
The mean per-cycle cost-saving resulting from using
clomiphene citrate was thus 2,620 Euros, which would
allow financing of an additional cycle with clomiphene
citrate for every 1.03 cycles with the use of high-dose
gonadotropins. The mean costs per delivery were 81,294
and 113,107 Euros in the clomiphene citrate and high-
dose gonadotropins groups, respectively. The costs
required to achieve an additional delivery in the high-
dose gonadotropins group was 192,639 Euros. A sensi-
tivity analysis based on the 95%CI of the DRs in the two
groups was not conclusive. At one extreme, costs per
delivery in the clomiphene citrate and high-dose gona-
dotropins groups were 41,000 and 271,100 Euros, re-
spectively. At the opposite extreme, they were 60,300 for
the latter group and 280,300 Euros for the former one
(Table 4).Table 4 Costs per cycle in the two study groups
Items Clomiphene
(n=145)
High-dose rFSH
(n=146)
Medications
GnRH agonists - 13,434
Recombinant-FSH - 320,604
Clomiphene citrate 1,459 -
Progesterone 655 660
Subtotal for medications 2,113 334,698
Technical procedures
Cycle preparation and
monitoring
32,625 32,850
Oocyte retrieval 248,868 250,875
Embryo transfer 122,864 173,326
Subtotal for procedures 404,357 457,051
Total costs 406,470 791,749
Mean cost per patient 2,803 5,423
Mean cost per delivery (95%CI) a 81,294 (40,046-
280,324)
113,107 (60,254-
271,146)
Costs are reported in Euros.
a The 95%CIs were calculated based on the 95%CI of the delivery rate.Discussion
In women with compromised ovarian reserve selected
for IVF, clomiphene citrate and a short protocol with
high-dose gonadotropins are both associated with disap-
pointing results. The use of the latter regimen increased
the number of oocytes retrieved and the proportion of
women performing embryo transfer but not the delivery
rates. In fact, a regimen of ovarian stimulation using ex-
clusively clomiphene citrate may be considered in the
management of these women since the chances of suc-
cess did not markedly differ and this scheme is asso-
ciated with lower costs.
The disappointing chances of success in women with
compromised ovarian response are important data emer-
ging from our trial. In both arms of the study, the deliv-
ery rate was below 5%, corresponding to the definition
of “very poor prognosis” recently proposed by the Ethics
Committee of the American Society for Reproductive
Medicine [11]. One may argue that this may be at least
in part due to the low quality of the units involved. Even
if we cannot robustly refute this criticism, some contrary
arguments deserve to be mentioned. Firstly, during the
study period, the participating centres reported delivery
rates per started cycle for patients not included in the
trial in line with those of the national Italian ART regis-
ter. Secondly, all four units involved handled a consist-
ent number of couples annually (>1000 IVF cycles per
year) and all of them had a long-standing clinical and
scientific experience in IVF. Thirdly, the observed low
rate of success appears to be in agreement with data
from the literature on women with a compromised ovar-
ian reserve [12]. Finally, it should be emphasised that
the criteria used for the definition of compromised ovar-
ian reserve in this study were very stringent and we may
have selected a subgroup of women whose ovarian re-
serve is particularly damaged. From the health-provider
point of view, the appropriateness of this intervention is
inevitably questionable in these cases. Of note, our eco-
nomical model under-estimated the overall costs per de-
livery since it did not include the costs of pregnancy
assistance. More in-depth economic analyses are
required prior to drawing firm indications for guiding
health provider’s decisions in these cases.
Some aspects of our trial warrant clarification and dis-
cussion. Of utmost relevance here is that the trial was
closed prior to completing the scheduled sample size
and the power of the study is 60% in contrast to the ini-
tial calculation. Once the sample size has not been
achieved one cannot make definite conclusions. This is
especially true when the there is no difference between
the two arms indicating the possibility of a beta error. In
fact, the upper limit of the absolute reduction difference
in favour of the high-dose gonadotropins group (7%)
exceeded the 5% limit postulated as clinically relevant.
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curred despite the number of eligible patients being ad-
equate to fulfil recruitment within a two-year period
(Figure 1) and despite the initial assumptions for sample
size calculation not being stringent. In our view, the dif-
ficulty in recruitment reflects the negative prejudge-
ments women may have on an innovative approach
using exclusively clomiphene citrate. External condition-
ing from other infertile women, the media or the inter-
net may have played a role on this. We also cannot rule
out that at least some physicians engaged in recruitment
were somewhat reluctant to our study design, thus un-
consciously influencing the woman’s decision to decline
participation. Future studies aimed at testing mild
approaches for women with compromised ovarian re-
serve should consider in advance this difficulty. Results
of the present study may be of help in this regard since
they can be used to persuade physicians and eligible
subjects about the appropriateness of alternative, less
aggressive approaches. In this study, we planned a two-
year period of recruitment in order to maintain the con-
ditions of the studied population as stable as possible.
This point is of particular relevance in the field of IVF
since notions and practices are in rapid and constant
evolution. However, given the difficulties that we
encountered, in future trials, one may consider the pos-
sibility of extending the recruitment period beyond the
conventional limit of two years despite the intrinsic risk
of biases associated with prolonged enrolments. Unfor-
tunately, difficulties in recruitment do not allow us to
draw definite conclusions regarding the financial aspects.
The sensitivity analysis using the limits of the 95%CI of
the DRs was not conclusive because at the two extremes,
there were relevant economic advantages of one of the
two groups. As such, our data has to be intended as pre-
liminary and further study is warranted to clarify
whether clomiphene citrate should become the first-line
option in women with compromised ovarian reserve.
Some further aspects of the trial deserve to be noted.
Firstly, we decided to test clomiphene citrate rather then
natural cycle IVF because this is currently the cheapest
available option and because we had encouraging results
in a preliminary study with this approach [5]. The
underlying hypothesis tested is that, in a situation of
compromised ovarian reserve, the regimen of stimula-
tion is much less relevant than the patient herself in de-
termining the success of IVF. Natural cycle IVF was a
plausible alternative since it may appear at prima facie
cheaper but monitoring these cycles is more trouble-
some because of the risk of premature LH surge and this
may actually increase costs. In fact, some authors have
suggested employing a natural-cycle-guided IVF adding
GnRH antagonists and low-dose gonadotropins during
the last days of stimulation to prevent this deleteriousevent [13]. However, this is inevitably more expensive.
Overall, we deemed that clomiphene citrate represented
the less expensive option. It is noteworthy that prema-
ture LH surge is less likely with this drug because of its
long-lasting anti-oestrogen effects [14]. Accordingly, the
rate of premature luteinisation was similar in the two
arms of our study. The interest of clomiphene citrate in
this context is further supported by the observation that
the rate of cancellation was identical in the two arms of
our trial. In fact, although discarded in clinical practice,
IVF using exclusively clomiphene citrate can yield rea-
sonable results. A clinical pregnancy rate per started
cycle and per embryo transfer of 18% and 34% have been
reported [15].
Secondly, the choice of a short protocol regimen as a
comparator may also be a concern. As mentioned earlier,
the most appropriate regimen for poor responders has
yet to be established. Evidence on this point is confusing.
Nevertheless, there is some data suggesting that the
short protocol regimen may be more suitable in poor
responders [3].
Thirdly, the inclusion criteria used to define poor
responders may also be a point of debate. Until recently,
a shared definition of this condition was lacking. How-
ever, in 2010, opinion leaders in this area met within an
ESHRE consensus meeting in order to propose a unique
definition [4]. The presence of at least two of the follow-
ing features are now necessary to define poor respon-
ders: 1) advanced maternal age (≥40 years) or any other
risk factors for poor response;2) previous poor ovarian
response (≤3 oocytes retrieved with a conventional
stimulation protocol);and 3) an abnormal ovarian re-
serve test (AFC<5-7 follicles or AMH<0.5-1.1 ng/ml).
Two episodes of poor response after maximal stimula-
tion is an additional condition to define poor responders.
In our study, we could not use these criteria since they
were published after the study was implemented. How-
ever, it has to be emphasised that at least 278 women
(96%) fulfilled this definition. An additional questionable
point in this regard is the use of serum FSH as a unique
selection criterion for a subgroup of included subjects.
More than one criterion to characterise a woman as a
poor responder is generally recommended [16]. How-
ever, it has to be pointed out that the use of serum FSH
to predict poor responsiveness is arguable because of a
high rate of false negatives (normal FSH but poor re-
sponse) rather than the opposite (high FSH but normal
response). Serum FSH is actually a late marker of com-
promised ovarian reserve. In fact, our decision led us to
exclude some women with compromised ovarian reserve
rather than including subjects with normal ovarian re-
serve. The analysis focussing exclusively on women
recruited based on elevated serum FSH (see Table 3)
confirmed this view. On the other hand, the selection
Ragni et al. Reproductive Biology and Endocrinology 2012, 10:114 Page 8 of 8
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ation of our results and it has to be remembered that
inferences should be done exclusively to the specific
population in our study.
Fourthly, the study was un-blinded. However, the im-
pact of this potential bias is presumably small because
the funding source was impartial to the treatments stud-
ied and a relevant role of the placebo effect in this kind
of context is questionable [17]. Finally, it is worth men-
tioning that baseline characteristics of the two groups
were similar, thus supporting the view that randomisa-
tion effectively prevented biases in allocation in our trial.
Only duration of infertility slightly differed. However,
this variable was not found to influence the chances of
success by logistics regression analysis, thus excluding a
critical confounding effect.
Conclusions
In conclusion, we failed to document marked differences
between clomiphene citrate and a short protocol with
high doses of gonadotropins in women requiring IVF
who were diagnosed with a compromised ovarian re-
serve based on day 3 serum FSH persistently above
12 IU/ml or a history of previous poor response (≤ 3
oocytes with a conventional stimulation protocol). Given
the lower costs associated with the use of clomiphene
citrate, this regimen may be considered in the manage-
ment of these women. However, further evidence is
required mainly because of the unusually low delivery
rates observed in our trial. In fact, this exceedingly low
rate of success and the relatively small sample size does
not permit a valid statistical non-inferiority assessment.
Moreover, economic analyses cannot be viewed as defin-
ite because of the particular and unusual criteria used to
select our population. External validation of the low suc-
cess rate in this particular group of women is thus ne-
cessary prior to confirm the unfavourable profile of our
costs calculations.
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